When was SphingoTec founded?

SphingoTec was founded in 2002 and raised its 1st funding round 13 years after it was founded.

Where is SphingoTec located?

SphingoTec is headquartered in Hennigsdorf, Germany. It is registered at Neuendorfstr. 15A 16761 Hennigsdorf.

Which legal entities is SphingoTec associated with?

SphingoTec is associated with Sphingotec Gmbh.

How many employees does SphingoTec have?

As of Jun 30, 2026, the latest employee count at SphingoTec is 19.

Is SphingoTec a funded company?

SphingoTec is a funded company, having raised a total of $36.1M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 01, 2015.

When was the latest funding round of SphingoTec?

SphingoTec's latest funding was a $***** Series C round on Aug 08, 2024, with participation from 5 investors.

Where does SphingoTec rank among its competitors?

SphingoTec ranks 14th amongst 145 active competitors, of which 43 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Volition, which secured an undisclosed amount in Mar, 2026.

Who are the top competitors of SphingoTec?

SphingoTec's top competitors include OpGen, CytoVale and Volition. Among them, Volition secured the most recent funding round in March, 2026.

SphingoTec - 2026 Company Profile, Team, Funding, Competitors & Financials

SphingoTec is a series C company based in Hennigsdorf (Germany), founded in 2002 by Andreas Bergmann. It operates as a Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases. SphingoTec has raised $36.1M in funding from investors like Brandenburg Capital, Wellington Partners Venture Capital and HBM Healthcare Investments. The company has 145 active competitors, including 43 funded and 17 that have exited. Its top competitors include companies like OpGen, CytoVale and Volition.

Company Details

Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases. The company is involved in the development of biomarker-based in-vitro diagnostic solutions for the treatment of critical medical conditions, such as sepsis, acute heart failure, circulatory failure, and acute kidney injury. It develops a PenKid platform that measures the levels of renal hormone enkephalin and uses it to predict creatinine levels in the near future. Bio-ADM measures levels of Adrenomedullin as a biomarker for circulatory shock and vasopressor demand. It has also developed a pro-NT biomarker that measures the levels of proneurotensin to predict the risk of obesity, cardiovascular disease, and breast cancer. It provides a vr-hGH platform that measures levels of human growth hormone to predict cardiovascular risk in men.

Website: sphingotec.com
Social
Email ID: *****@sphingotec.com, *****@sphingotec.com
Phone Number: +49 **********
Registered Address: Neuendorfstr. 15A 16761 Hennigsdorf

Key Metrics

Founded Year

2002

Location

Hennigsdorf, Germany

Stage

Series C

Total Funding

$36.1M in 6 rounds

Latest Funding Round

Series C, Aug 08, 2024, $*****

Investors

Brandenburg Capital & 17 more

Ranked

14^th among 145 active competitors

Employee Count

19 as on Jun 30, 2026

Similar Companies

CytoVale & 52 more

View SphingoTec's full profile

SphingoTec is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Sphingotec Gmbh CIN: HRB6264 , Germany, Active	May 21, 2002	-	36 (As on Dec 31, 2020)

SphingoTec has raised a total funding of $36.1M over 6 rounds. Its first funding round was on Apr 01, 2015. Its latest funding round was a Series C round on Aug 08, 2024 for $*****. 5 investors participated in its latest round. SphingoTec has 9 institutional investors and 9 angel investors.

Here is the list of recent funding rounds of SphingoTec:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Aug 08, 2024	2702345	Series C	5456119	3825864	2974715	8825895
Dec 05, 2019	6377308	Series B	2439407	9159134	3007399	2119036
Oct 08, 2018	7257721	Series A	4874425	2984002	HBM Healthcare Investments & 1 more	HBM Partners

Access funding benchmarks and valuations. Sign up today!

View details of SphingoTec's funding rounds and investors

The founders of SphingoTec is Andreas Bergmann. Jorg Menten is the CEO of SphingoTec.

Here are the details of SphingoTec's key team members:

Andreas Bergmann: Founder of SphingoTec. They serve on the board of 1 company.

SphingoTec's Board of Directors

SphingoTec's board has 1 active member. Jorg Menten is part of team.

Here is the list of SphingoTec's board of directors:

Name	Type	Representing	Status	Duration
dvxohgm	Team	-	Past	3y 9m
uppoaxn	Team	-	Current	4y 1m
fygeisr	Independent board member	-	Past	2y 3m

View details of SphingoTec's Founder profiles and Board Members

SphingoTec's employee count trend

SphingoTec has 19 employees as of Jun 26. Here is SphingoTec's employee count trend over the years:

Uncover SphingoTec's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of SphingoTec include OpGen, CytoVale and Volition. Here is the list of Top 10 competitors of SphingoTec, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	OpGen 2002, Rockville (United States), Public	Developer of diagnostics and bioinformatics platforms for providers	$77.5M	Cross Creek, 180 Degree Capital & 12 others	67/100
2nd	CytoVale 2013, San Francisco (United States), Series D	Microfluidic-based biomarkers for the early detection of sepsis	$207M	Sands Capital, Blackhorn Ventures & 19 others	62/100
3rd	Volition 1995, Gembloux (Belgium), Public	Developer of cancer diagnostic tests	-	Namur Invest, Belgium & 1 others	61/100
4th	DNA Electronics 2003, London (United Kingdom), Series C	Developer of semiconductor‑based DNA‑sequencing systems for use in healthcare	-	Citi, Genting Group & 1 others	54/100
5th	Earth Science tech 2014, Doral (United States), Public	Developer of a medical device for detection of chlamydia	-	-	52/100
6th	Bluejay Diagnostics 2015, Acton (United States), Public	Non-invasive point-of-care diagnostic solutions	$3.73M	Centrecourt Asset Management	50/100
7th	Abionic 2010, Epalinges (Switzerland), Series C	Provider of point-of-care diagnostic tool for allergy profiles	$28.9M	Venture Kick, MedHoldings & 17 others	49/100
8th	Avails Medical 2013, Menlo Park (United States), Series A	Rapid AST technology for faster, actionable results in bloodstream infections	$8.66M	CARB-X, Yijing Capital & 4 others	49/100
9th	Q-linea 2008, Uppsala (Sweden), Public	Fully automated platforms for pathogen detection	$18.3M	Nxt2b, SwediaCapital & 2 others	48/100
10th	HandyLab 1999, Ann Arbor (United States), Acquired	Developer of molecular diagnostic assays and automation platforms	$44M	Dow Chemical Company, Ann Lurie & 7 others	48/100
14th	SphingoTec 2002, Hennigsdorf (Germany), Series C	Developer of biomarker-based diagnostic solutions for cancer, cardiovascular, and other diseases	$36.1M	HBM Healthcare Investments, Think.Health ... & 16 others	44/100